Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002632
Status:
COMPLETED
Last Update Posted:
2023-06-15
First Post:
1999-11-01
Brief Title:
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Sponsor:
Eastern Cooperative Oncology Group
Organization:
Eastern Cooperative Oncology Group
Study Overview
Official Title:
PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer
Detailed Description:
OBJECTIVES I Estimate the response rate in patients with metastatic or recurrent salivary gland cancer treated with paclitaxel Taxol TAX by 3-hour infusion II Describe the toxicity of TAX in these patients
OUTLINE Single-Agent Chemotherapy Paclitaxel Bristol-Myers Taxol TAX NSC-125973
PROJECTED ACCRUAL Up to 32 patientshistology will be entered If no response is observed in the first 14 patients in a particular histology accrual to that group will close if after 18 months annual accrual is less than 10 patientshistology accrual to that group may close
OUTLINE Single-Agent Chemotherapy Paclitaxel Bristol-Myers Taxol TAX NSC-125973
PROJECTED ACCRUAL Up to 32 patientshistology will be entered If no response is observed in the first 14 patients in a particular histology accrual to that group will close if after 18 months annual accrual is less than 10 patientshistology accrual to that group may close
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| E-1394 | None | None | None |